Cancer Research Cell Death Mechanisms and Cancer Therapy  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alli, E.
Right arrow Articles by Hait, W. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alli, E.
Right arrow Articles by Hait, W. N.
[Cancer Research 62, 6864-6869, December 1, 2002]
© 2002 American Association for Cancer Research


Experimental Therapeutics

Effect of Stathmin on the Sensitivity to Antimicrotubule Drugs in Human Breast Cancer1

Elizabeth Alli, Judy Bash-Babula, Jin-Ming Yang and William N. Hait2

The Cancer Institute of New Jersey, Departments of Medicine and Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, New Jersey 08901

Stathmin is a p53-regulated protein known to influence microtubule dynamics. Because several chemotherapeutic agents used to treat breast cancer alter the dynamic equilibrium of tubulin polymerization, stathmin may play an important role in determining the sensitivity to these drugs. Therefore, we evaluated the effect of stathmin expression on the action of taxanes and Vinca alkaloids using a panel of human breast cancer cell lines. Cell lines harboring mutant p53 expressed high levels of stathmin. Two cell lines with different levels of endogenous stathmin expression and isogenic-paired cell lines transfected to overexpress stathmin were used to determine whether or not stathmin modulated the sensitivity to drugs. Overexpression of stathmin decreased polymerization of microtubules, markedly decreased binding of paclitaxel, and increased binding of vinblastine. Stathmin overexpression decreased sensitivity to paclitaxel and, to a lesser extent, to vinblastine. In contrast, stathmin content had no significant effect on the sensitivity to chemotherapeutic drugs that do not target microtubules. Cell lines overexpressing stathmin were more likely to enter G2 but less likely to enter mitosis as determined by fluorescence-activated cell sorting and mitotic index. This effect was magnified when stathmin-overexpressing cells were treated with vinblastine as measured by the detection of proteins phosphorylated in early mitosis. These data suggest that the action of antimicrotubule drugs can be affected by stathmin in at least two ways: (a) altered drug binding; and (b) growth arrest at the G2 to M boundary. Mutant p53 breast cancers exhibiting high levels of stathmin may be resistant to antimicrotubule agents.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
E. A. Perez
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
Mol. Cancer Ther., August 1, 2009; 8(8): 2086 - 2095.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Singer, M. Malz, E. Herpel, A. Warth, M. Bissinger, M. Keith, T. Muley, M. Meister, H. Hoffmann, R. Penzel, et al.
Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Non-Small Cell Lung Cancer
Cancer Res., March 15, 2009; 69(6): 2234 - 2243.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Aoki, Y. Oda, S. Hattori, K.-i. Taguchi, Y. Ohishi, Y. Basaki, S. Oie, N. Suzuki, S. Kono, M. Tsuneyoshi, et al.
Overexpression of Class III {beta}-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma
Clin. Cancer Res., February 15, 2009; 15(4): 1473 - 1480.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
P. Lohavanichbutr, J. Houck, W. Fan, B. Yueh, E. Mendez, N. Futran, D. R. Doody, M. P. Upton, D. G. Farwell, S. M. Schwartz, et al.
Genomewide Gene Expression Profiles of HPV-Positive and HPV-Negative Oropharyngeal Cancer: Potential Implications for Treatment Choices
Arch Otolaryngol Head Neck Surg, February 1, 2009; 135(2): 180 - 188.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. P. Newman, P. A. Foster, C. Stengel, J. M. Day, Y. T. Ho, J.-G. Judde, M. Lassalle, G. Prevost, M. P. Leese, B. V.L. Potter, et al.
STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells
Clin. Cancer Res., January 15, 2008; 14(2): 597 - 606.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Guan, X.-r. Wang, X.-f. Zhu, X.-f. Huang, J. Xu, L.-h. Wang, X.-b. Wan, Z.-j. Long, J.-n. Liu, G.-k. Feng, et al.
Aurora-A, a Negative Prognostic Marker, Increases Migration and Decreases Radiosensitivity in Cancer Cells
Cancer Res., November 1, 2007; 67(21): 10436 - 10444.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. M.R. Bhat and V. Setaluri
Microtubule-Associated Proteins as Targets in Cancer Chemotherapy
Clin. Cancer Res., May 15, 2007; 13(10): 2849 - 2854.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. H. Saal, P. Johansson, K. Holm, S. K. Gruvberger-Saal, Q.-B. She, M. Maurer, S. Koujak, A. A. Ferrando, P. Malmstrom, L. Memeo, et al.
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
PNAS, May 1, 2007; 104(18): 7564 - 7569.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
E. Alli, J.-M. Yang, J. M. Ford, and W. N. Hait
Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma Cells
Mol. Pharmacol., May 1, 2007; 71(5): 1233 - 1240.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
N. Muthukumaran, K. E. Miletti-Gonzalez, A. K. Ravindranath, and L. Rodriguez-Rodriguez
Tumor Necrosis Factor-{alpha} Differentially Modulates CD44 Expression in Ovarian Cancer Cells
Mol. Cancer Res., August 1, 2006; 4(8): 511 - 520.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. H. Soltani, R. Pichardo, Z. Song, N. Sangha, F. Camacho, K. Satyamoorthy, O. P. Sangueza, and V. Setaluri
Microtubule-Associated Protein 2, a Marker of Neuronal Differentiation, Induces Mitotic Defects, Inhibits Growth of Melanoma Cells, and Predicts Metastatic Potential of Cutaneous Melanoma
Am. J. Pathol., June 1, 2005; 166(6): 1841 - 1850.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Honore, K. Kamath, D. Braguer, S. B. Horwitz, L. Wilson, C. Briand, and M. A. Jordan
Synergistic Suppression of Microtubule Dynamics by Discodermolide and Paclitaxel in Non-Small Cell Lung Carcinoma Cells
Cancer Res., July 15, 2004; 64(14): 4957 - 4964.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.